Skip to main
ODTX

ODTX Stock Forecast & Price Target

ODTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Odyssey Therapeutics is an innovative company with strong potential in the biopharmaceutical market, backed by their partnership with JNJ and promising pipeline assets. With their focus on targeting multiple cytokines and utilizing advanced technology, they are well-positioned to address the growing demand for effective treatments for autoimmune diseases like lupus and IBD. The company also has a healthy financial standing, evident from their $2.5 million in revenue in 2025 and the expected growth of the market for IBD treatments.

Bears say

Odyssey Therapeutics is a clinical-stage biopharmaceutical company focusing on autoimmune and inflammatory diseases. The limited clinical validation of Odyssey's novel target, SLC15A4, and the risk of failure to meet primary endpoints or below expected efficacy in the company's ongoing studies lead to a negative outlook. Additionally, safety signals could emerge from the studies. However, the company's unique approach using scaffolding targeting instead of kinase inhibition for their lead asset, OD-001, along with its benign safety profile and competitive phase 2a data, gives some confidence in the upcoming combination and monotherapy trials. The company's novel program targeting TNFR2 also shows potential, but the limited validation and competition from similar approaches could hinder its success.

ODTX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Odyssey Therapeutics Inc (ODTX) Forecast

Analysts have given ODTX a Buy based on their latest research and market trends.

According to 4 analysts, ODTX has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Odyssey Therapeutics Inc (ODTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.